H60.1 (Repligen)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameH60.1 (Repligen)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment

Mechanisms of ActionIntegrin antagonists

TargetsIntegrin

Therapy Area/IndicationsStrokeRespiratory Distress Syndrome, NewbornPneumonia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesRepligen

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRepligen

Active IndicationsN/A

Inactive IndicationsStrokeRespiratory Distress Syndrome, NewbornPneumonia

Other Information

ATC CodeN/A